Dr. Pulsipher is currently the Division Chief of the Pediatric Hematology at Intermountain Primary Children's Hospital and Oncology, Director of the Children's and Adolescent Cancer Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah.  Dr. Pulsipher is an internationally recognized expert in Bone Marrow Transplantation and Cellular Therapy, having directed the world's largest pediatric transplant research group for more than a decade (Pediatric Transplantation and Cellular Therapy Consortium).  He has run more than 20 multicenter trials in the field and is considered and expert in broad areas of transplantation and cellular therapy.  Areas of focus have included development of reduced toxicity approaches to transplantation of both malignant and non-malignant disorders with a focus on minimizing short and long-term effects of transplant.  For non-malignant disorders he has run national protocols that have improved safety for patients with immunodeficiencies, HLH, and bone marrow failure. For cancer, he has developed techniques allowing identification of patients who can avoid radiation-based treatments for leukemia.  This has included a novel approach to safer transplantation of patients using half-matched family donors (haploidentical donors) using a novel form of bone marrow graft engineering called alpha-beta T-cell depletion.  His desire to develop safer approaches has become a major focus as he has led major studies in the field of chimeric antigen receptor T-cells (CAR T-cells), a safer approach to cancer cure.  Dr. Pulsipher's work in cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies. He has open protocols aimed at improving outcomes and his lab efforts are focused on making CAR T-cells that last longer and avoid overcome resistance by cancer cells. Dr. Pulsipher's interests have included ensuring that the families of those undergoing transplantation and cell therapy are psychologically well throughout the process.  To help with this, he has run several large trials assessing the safety and Quality of Life of pediatric bone marrow donors and is he currently running a large national trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652. For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830. Dr. Pulsipher is highly rated in 16 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant.

Dr. Meznarich received her medical degree from the University of Washington School of Medicine in Seattle, Washington. She then completed her residency in Pediatrics and fellowship in Pediatric Hematology and Oncology at the University of Utah/Primary Children's Hospital in Salt Lake City, Utah.She joined the faculty of the University of Utah in 2016, where she is currently an Associate Professor of Pediatrics in the Division of Pediatric Hematology and Oncology.  Her clinical and research interests are in non-malignant hematology, bleeding disorders, thrombosis and clotting disorders, and hemoglobinopathies including thalassemia and sickle cell disease. Dr. Meznarich is highly rated in 5 conditions, according to our data. Her top areas of expertise are Dyserythropoietic Anemia and Thrombocytopenia, Anemia, Pure Red Cell Aplasia, and Aase Syndrome.

Richard Lemons, MD, PhD, is a professor in the Department of Pediatrics at the University of Utah School of Medicine, medical director and chief of pediatric hematology/oncology at Primary Children's Medical Center and the University of Utah, and a Huntsman Cancer Institute investigator. He is involved in various clinical trials for pediatric malignancies and pediatric hematologic disorders.Lemons earned a medical degree from George Washington University School of Medicine, Washington, DC; and performed an internship and residency at Johns Hopkins Hospital, Baltimore. Lemons was a staff member at St. Jude Children's Research Hospital prior to joining the University of Utah Department of Pediatrics. He is board certified in Pediatrics and Pediatric Hematology-Oncology. Dr. Lemons is highly rated in 3 conditions, according to our data. His top areas of expertise are Hemophilia B, Infantile Neutropenia, Blood Clots, and Febrile Neutropenia.

Dr. McNeer is a Professor of Clinical Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology and is the Medical Director for Pediatric Hematology/Oncology at Primary Children's Hospital. She is a member of the Leukemia and Lymphoma team at the University of Utah and Primary Children's Hospital.After receiving her medical degree from New York University School of Medicine, Dr. McNeer completed her residency at Children's Memorial Hospital (now Lurie Children's Hospital), which is affiliated with Northwestern University Feinberg School of Medicine. She then completed her fellowship in Pediatric Hematology/Oncology/Stem Cell Transplant at Children's Memorial Hospital, and during her fellowship earned a master's degree in clinical investigation at Northwestern University Feinberg School of Medicine.Dr. McNeer is board-certified in Pediatrics and Pediatric Hematology and Oncology. She has authored over 25 peer-reviewed journal articles and 4 book chapters. Dr. McNeer has been an invited speaker at many national and international conferences and symposiums. She is a member of the American Society of Clinical Oncology, American Society of Hematology, as well as the American Society of Pediatric Hematology/Oncology and the Children's Oncology Group.Dr. McNeer's clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, in particular those with high-risk and relapsed/refractory acute lymphoblastic leukemia. She has a leadership role within the Children's Oncology Group Acute Lymphoblastic Leukemia committee, and partners with colleagues in adult oncology to collaborate in developing treatment protocols and clinical trials for young adults with leukemia. Her research focus is on the design and implementation of clinical trials for patients with hematologic malignancies.Dr. McNeer is invested in improving overall treatment outcomes for children, adolescents, and young adults, while tailoring therapy and supportive care to individual patients in order to minimize toxicity and optimize quality of life. Dr. Mcneer is highly rated in 2 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Infantile Neutropenia, and Bone Marrow Aspiration.

Luke Maese is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Maese is highly rated in 3 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Rhabdomyosarcoma, and Adult Soft Tissue Sarcoma.

Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs. Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network. Dr. Dietz is highly rated in 7 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

Dr. Mangum received his medical degree from the Albert Einstein College of Medicine (affiliated with Yeshiva University). He then completed his Pediatric residency at Primary Children´s Hospital (affiliated with the University of Utah), which was followed by a pediatric Hematology Oncology Fellowship at St Jude Children's Research Hospital (affiliated with the University of Tennessee). Afterwards, he completed an additional two year Physician Scientist Training Program fellowship at St. Jude Children's Research Hospital while still also continuing to care for patients. Following this, Dr. Mangum joined the faculty of Nemours Children's Hospital in Delaware where he practiced for three years in pediatric hematology oncology. Dr. Mangum then joined the University of Utah in the Division of Pediatric Hematology Oncology at Primary Children's Hospital. Dr. Mangum's research interests have focused primarily on Acute Lymphoblastic Leukemia, with his clinical interests focused on patients with Leukemias, Lymphomas, and histiocytic disorders of all kinds. However, he is comfortable with caring for any patient across the entire pediatric hematology oncology spectrum. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Rosai-Dorfman Disease, and Immune Thrombocytopenic Purpura (ITP).

Dr. Dolan received his medical degree from the University of Washington and completed his Pediatric residency at Seattle Children´s Hospital.  He went on to pursue his Pediatric Hematology and Oncology Fellowship and advanced fellowship in cellular/immunotherapy and bone marrow transplant at the Children's Hospital of Philadelphia. He joined the faculty of the University of Utah in 2021 as an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology.Dr. Dolan's clinical interests include the treatment of pediatric disorders requiring bone marrow transplant.  He has an emphasis on high-risk hematologic malignancies and cellular therapy designed to reduce toxicity in patients with relapsed and refractory disease.His primary research focuses on outcomes of children treated with cellular/immunotherapy products. He also has an interest in understanding the emotional and spiritual challenges that arise as part of the journey for patients and families diagnosed with cancer. His top areas of expertise are Hereditary Neuroblastoma, Neuroblastoma, Acute Lymphoblastic Leukemia (ALL), and Immune Thrombocytopenic Purpura (ITP).

Dr. Chan received her medical degree from the University of Minnesota Medical School, completed her Pediatric Residency at the University of Wisconsin, and her Pediatric Hematology/Oncology Fellowship at the University of Utah. Following fellowship she completed a Pediatric Neuro-Oncology Fellowship at the University of Colorado/Children's Hospital Colorado.Dr. Chan is currently an Assistant Professor of Pediatrics at the University of Utah in the Division of Pediatric Hematology/Oncology. She is a member of the neuro-oncology team at Primary Children's Medical Center.Dr. Chan's clinical interests include the care of children and young adults with brain and spine tumors. Dr. Chan's research interests are focused on the development of early phase clinical trials for children with central nervous system tumors and the long-term care of patients who have survived these cancers. Her top areas of expertise are Glioma, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Immune Thrombocytopenic Purpura (ITP).

Dr. Fraley received her medical degree from the University of New Mexico School of Medicine, followed by a Pediatrics residency at Oregon Health & Science University. She then completed a Pediatric Hematology, Oncology, and Bone Marrow Transplant fellowship at Children's Hospital Colorado where she received additional training in clinical research through the Masters of Clinical Science program at the University of Colorado Anschutz Medical Campus. Dr. Fraley was an Instructor of Pediatrics for an additional year at Children's Hospital Colorado, where she continued to care for patients while also developing a program of research studying neurocognitive outcomes in children with cancer and blood disorders.Dr. Fraley is currently an Assistant Professor of Pediatrics at the University of Utah and is in the Division of Pediatric Hematology Oncology. Clinically, she cares for patients with leukemia and lymphoma as well as long term survivors of all cancers. Dr. Fraley's program of research examines neurocognitive dysfunction (i.e., difficulties with thinking, learning, and remembering) in childhood cancer survivors, including risk factors for dysfunction, the consequences of dysfunction, and interventions to prevent decline. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL) and Immune Thrombocytopenic Purpura (ITP).

Dr. Thomsen received his medical degree from the University Of Virginia School Of Medicine.  He completed a residency in general pediatrics at Wake Forest Baptist Medical Center where he also served as chief resident and practiced as a pediatric hospitalist.  He completed his clinical fellowship in pediatric hematology and oncology at the University of Utah.  He is currently an Assistant Professor in the Pediatric Hematology and Oncology Division at the University of Utah.Dr. Thomsen's clinical interests include care of children with childhood leukemia, lymphoma and various other cancers.  Dr. Thomsen's research focuses on improving care of children with childhood cancer by applying quality improvement principles to everyday care.  He is passionate about medical education and improving hematology-oncology education in pediatric residency programs and has a keen interest in improving access to pediatric hematology-oncology services throughout the intermountain west. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Glioma, Hereditary Neuroblastoma, and Neuroblastoma.

Dr. Casey Mehrhoff received her Master of Science in Biomedical Sciences and medical degree from Kansas City University of Medicine, completed her Pediatric Residency at Loyola University Medical Center in Chicago, and her Pediatric Hematology/Oncology Fellowship at Ann & Robert H. Lurie Children's Hospital of Chicago. She is currently an Assistant Professor of Pediatrics at the University of Utah within the Division of Pediatric Hematology/Oncology at Primary Children's Hospital. Her clinical focus is on pediatric patients with solid tumor malignancies, with a specific focus on patients diagnosed with rare tumors and patients with cancer predisposition syndromes. She is the co-director and co-founder of the Pediatric Multidisciplinary Thyroid Team and is the co-director and founder of the Pediatric Multidisciplinary Melanoma program and is involved with these specialties on a national level. She is a provider in the high risk genetics cancer predisposition clinic at Huntsman Cancer Institute where she provides care and cancer screening for patients with certain cancer predisposition syndromes, such as Li Fraumeni Syndrome, DICER1, and Familial Adenomatous Polyposis, to name a few. Her research interest is in translational research and clinical trials. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Acute Lymphoblastic Leukemia (ALL), and Immune Thrombocytopenic Purpura (ITP).

Caleb Hocutt is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. His top areas of expertise are Pure Red Cell Aplasia, Aase Syndrome, Aplastic Anemia, and Transient Erythroblastopenia of Childhood.

Elaine Fan is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Her top areas of expertise are Pure Red Cell Aplasia, Aase Syndrome, Shwachman-Diamond Syndrome, and Hereditary Spherocytosis.

Dr. Ford is currently an associate professor at the University of Utah School of Medicine in the division of Pediatric Hematology/Oncology. He is a member of the Leukemia and Lymphoma Team at the University of Utah and Primary Children's Hospital. He received his medical degree from Des Moines University College of Osteopathic Medicine.Dr. Ford completed his residency at Akron Children's Hospital specializing in Pediatrics. He pursued his Hematology, Oncology and Bone Marrow Transplantation Fellowship at the University of Colorado School of Medicine, Children's Hospital Colorado.Dr. Ford is board-certified in Pediatrics and Pediatric Hematology and Oncology. He has authored several articles in peer-reviewed journals and has been the principal investigator in several grants.Dr. Ford's clinical interests include the treatment of pediatric Leukemia and Lymphoma. He has an emphasis in post-transplant lymphoproliferative disorder and Non-Hodgkin Lymphomas.His primary research focuses on Non-Hodgkin Lymphoma. He is involved in clinical trials for relapsed T-cell lymphoblastic lymphoma and relapsed mature B cell lymphoma. He is also interested in discovering risk factors leading to relapse in T-cell lymphoblastic lymphoma. His top area of expertise is Immune Thrombocytopenic Purpura (ITP).

Sara Dryden is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Her top area of expertise is Immune Thrombocytopenic Purpura (ITP).

Bar Devald is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. His top area of expertise is Immune Thrombocytopenic Purpura (ITP).

Angela Parra is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Her top area of expertise is Immune Thrombocytopenic Purpura (ITP).